Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors
نویسندگان
چکیده
Metastatic renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is associated poor survival outcomes. We aimed to analyze the efficacy and safety of immune checkpoint inhibitors (ICI) in patients sRCC comparing clear-cell (sccRCC) non-clear epithelial histology (snccRCC). performed retrospective analysis who received ICI at MD Anderson Cancer Center (n = 48, 41 ccRCC 7 nccRCC) determine overall (OS), progression-free (PFS), objective response rate (ORR). Additionally, we a prespecified multivariable Cox regression outcomes between sccRCC snccRCC. The ORR for entire cohort was 35.4% (95% confidence interval [CI]: 23.4%, 49.6%), including 8 (16.7%) CI: 8.7%, 29.6%) achieved complete remission. disease control 52% 38.3%, 65.5%). In sccRCC, 39% 25.7%, 54.3%) 58.5% (43.4%, 72.2%). Among snccRCC patients, only one (14.3%) an partial response. At median follow-up 51.1 months, PFS 4.9 months 2.7, 16.3) OS 28.4 15.8, NA) cohort. For 8.9 30.1 compared 2.3 (HR 0.25 [95% 0.08, 0.78]; P= 0.0145) 6.7 0.13 CI 0.04, 0.44]; P=0.0009) ICIs appear be effective while treatment remains challenging.
منابع مشابه
Sarcomatoid Chromophobe Renal Cell Carcinoma with Heterologous Component
Clear cellrenal cell carcinoma (RCC) is the most common malignant renal tumor in adults, while chromophobe RCC (CRCC) is the third most common. Any subtypes of RCC can undergo sarcomatoid differentiation, but heterologous differentiation in sarcomatoid area is very rare in RCC. Here a61-year male is presented with hematuria and palpable mass. Clinicoradiologically, RCC was considered and left r...
متن کاملImmune checkpoint inhibitors in renal cell carcinoma
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain. Renal cancer was, historically, one of a small number of tumour types where immune manipulation had been shown to be effective. The current generation of immune checkpoint inhibitors are rapidly entering into routine clinic...
متن کاملSurvival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
Metastatic renal cell carcinoma with sarcomatoid histology (SmRCC) is associated with poor survival. No data is available from randomized trials on the efficacy of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors in SmRCC. We identified SmRCC patients from a single institutional database. To identify predictive and prognostic biomarkers, immunohistoc...
متن کاملTreatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
BACKGROUND The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma (RCC) were primarily conducted in patients with clear-cell histology (ccRCC). We assessed outcome with these mammalian target of rapamicin (mTOR) inhibitors in two subsets of kidney cancer: sarcomatoid variant ccRCC and nonclear-cell RCC. PATIENTS AND METHODS Basel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Urologic Oncology-seminars and Original Investigations
سال: 2021
ISSN: ['1873-2496', '1078-1439']
DOI: https://doi.org/10.1016/j.urolonc.2020.10.019